News articles about Infinity Pharmaceuticals (NASDAQ:INFI) have been trending positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of 0.31 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.8493119379919 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Infinity Pharmaceuticals stock traded down $0.10 during mid-day trading on Friday, hitting $1.87. The company had a trading volume of 913,648 shares, compared to its average volume of 746,195. The firm has a market capitalization of $104.44, a P/E ratio of -2.25 and a beta of 2.49. Infinity Pharmaceuticals has a 1 year low of $0.93 and a 1 year high of $3.75.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Thursday, March 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. sell-side analysts predict that Infinity Pharmaceuticals will post -0.74 earnings per share for the current year.
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.